Merck & Co. Inc. (MRK)

NYSE: MRK · USD

$128

+0.04 (+0.0%)· Recorded snapshot

Coverage state: Latest published research available

Market snapshot recorded 2026-08-07 02:00 UTC. Latest published research analyzed 2026-05-08 · historical · sources unverified. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate a fresh MRK analysis

The published report stays available while a new owner-requested analysis runs.

StockMarketAgent Research · Analyzed 2026-05-08

Our latest published analysis: MRK rated Hold

Hold. Valuation balances near-term strength against back-half transition risks.

Fair value (mid)

$121 / share

$94.9 – $147

Upside to FV

+7.4%

from $128

Confidence

84/100

Moat

9/10

Read full analysis →

Market cap	$277.4B
Revenue (ttm)	66.6B
Net income (ttm)	3.2B
EPS (ttm)	$1.27
Shares out	2.5B
P/E (trailing)	100.9x
P/E (forward)	11.8x
Dividend	$3.40 (2.65%)
Volume	7,051,986
Beta	0.21
Price target	$137	+6.5%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 66.6B
Net income (ttm): 3.2B
EPS (ttm): $1.27
P/E (trailing): 100.9x
P/E (forward): 11.8x
Market cap: $277.4B

Item	P1	P2	P3	P4	Trend
Period	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$59.28B	$60.12B	$64.17B	$65.01B	+3.1%
Gross profit	$41.87B	$43.99B	$48.98B	$48.63B	+5.1%
Operating income	$18.28B	$2.95B	$20.22B	$22.11B	+6.5%
Net income	$14.52B	$365.0M	$17.12B	$18.25B	+7.9%
EPS (diluted)	$5.71	$0.14	$6.74	$7.28	+8.4%
EBITDA	$21.32B	$6.91B	$25.71B	$28.26B	+9.9%
R&D	$13.55B	$30.53B	$17.94B	$15.79B	+5.2%
SG&A	$10.04B	$10.50B	$10.82B	$10.73B	+2.2%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ABBV	AbbVie Inc.	430.9B	69.6x	6.7x	17.7%	+3.7%	+26.6%	Hold
ABT	Abbott Laboratories	186.8B	34.9x	4.0x	7.5%	+3.0%	-15.5%	Strong Buy
ACN	Accenture plc	104.7B	13.7x	1.4x	27.1%	+8.8%	-28.4%	Buy
AMGN	Amgen Inc.	218.9B	25.2x	5.7x	19.8%	+8.4%	+39.0%	Strong Buy
BIIB	Biogen Inc.	30.5B	36.6x	3.0x	8.9%	-3.0%	+55.2%	Strong Buy
BMY	Bristol-Myers Squibb Company	131B	14.1x	2.7x	21.7%	+2.1%	+46.6%	Strong Buy

All MRK indicators

Market & fundamental data

Available fields

266

Groups with data

Currency

USD

Showing 266 of 266 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0000310158
Company name	Merck & Co., Inc.
Country	United States
Country code	US
Cusip	58933Y105
Employees	75,000
Employees Change	3,000%
Employees Change Percent	4.17
Enterprise value	$360.2B
Exchange	NYSE
Financial currency	USD
First seen	2026-05-09
In Index	SP500, DOW30
Industry	Drug Manufacturers - General
Industry PE	31.49
Industry PE Fwd	17.55
Isin	US58933Y1055
Last refreshed	2026-08-07
Market cap	$317.1B
Market cap category	Mega-Cap
Price	$128
Price currency	USD
Rev Per Employee	887,586.67x
Sector	Healthcare
Sector PE	49.12
Sector PE Fwd	22.46
Sic	2834
Symbol	MRK
Website	https://www.merck.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	1%
EV Earnings	113.53x
EV Sales Forward	5.3x
EV/EBIT	56.47x
EV/EBITDA	56.47x
EV/FCF	25.52x
EV/Sales	5.41x
FCF yield	4.46%
Forward P/E	14.88x
P/B ratio	6.91x
P/E ratio	100.85x
P/S ratio	4.76x
PE Ratio10 Y	56.04x
PE Ratio3 Y	100.29x
PE Ratio5 Y	71.09x
PEG ratio	2.2x
PS Forward	4.66x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	9.58%
EBITDA Margin	9.58%
FCF margin	21.46%
Gross margin	75.95%
Gross Profit	$50.6B
Gross Profit Growth	2.67%
Gross Profit Growth Q	-0.15%
Gross Profit Growth3 Y	5.8%
Gross Profit Growth5 Y	9.7%
Net Income	$3.2B
Net Income Growth	-80.66%
Net Income Growth Years	2%
Net Income Growth3 Y	0.66%
Net Income Growth5 Y	-10.64%
Pretax Margin	8.94%
Profit Margin	4.77%
Profit Per Employee	$42,307
Profitable Years	35
Roa5y	11.18
Roe5y	30.37
ROIC	5.88
Roic5y	22.36

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	11.1%
Cagr15y	13.76%
Cagr1y	64.26%
Cagr20y	9.84%
Cagr3y	10.27%
Cagr5y	14.7%
Div CAGR10	6.33%
Div CAGR3	5.2%
Div CAGR5	5.51%
EPS Growth	-80.37
EPS Growth Years	2
EPS Growth3 Y	1.25
EPS Growth5 Y	-10.38
FCF Growth	-17.16%
FCF Growth3 Y	7.82%
FCF Growth5 Y	16.21%
OCF Growth	-14.31%
OCF Growth10 Y	3.71%
OCF Growth3 Y	4.51%
OCF Growth5 Y	9.85%
Revenue Growth	4.64x
Revenue Growth Q	5.07x
Revenue Growth Quarters	3x
Revenue Growth Years	6x
Revenue Growth3 Y	4.51x
Revenue Growth5 Y	8.68x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Cash	$5.7B
Debt	$49.1B
Debt EBITDA	$7.7
Debt Equity	$1.07
Debt FCF	$3.48
Equity	$45.9B
Interest Coverage	4.7
Net Cash	$-43.4B
Net Cash By Market Cap	$-13.7
Net Debt EBITDA	$6.81
Net Debt Equity	$0.95
Net Debt FCF	$3.08
Tangible Book Value	$-1.4B
Tangible Book Value Per Share	$-0.59
WACC	4.88

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	1.92%
Dividend Growth	4.94%
Dividend Growth Years	15%
Dividend per share	$3.4
Dividend Years	56
Dividend Yield	2.65%
Ex Div Date	2026-09-15
Last Dividend	$0.85
Payout Frequency	Quarterly
Payout Ratio	267.12%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	186.5%
1Y total return	64.21%
200-day SMA	112.5
3Y total return	34.09%
50-day SMA	123.7
50-day SMA vs 200-day SMA	50over200
5Y total return	98.49%
All Time High	135.1
All Time High Change	-4.95%
All Time High Date	2026-07-28
All Time Low	1.02
All Time Low Change	12,436.13%
All Time Low Date	1968-03-25
ATR	3.41
Beta	0.21
Beta1y	-0.02
Beta2y	0.28
Ch YTD	21.96
High	131.1
High52	135.1
High52 Date	2026-07-28
High52ch	-4.95%
Low	127.8
Low52	77.58
Low52 Date	2025-09-25
Low52ch	65.47%
Ma50ch	3.79%
Premarket Change Percent	1.48
Premarket Price	$130
Premarket Volume	2,127
Price vs 200-day SMA	14.14%
RSI	53.89
RSI Monthly	63.73
RSI Weekly	61.74
Sharpe ratio	1.8x
Sortino ratio	3.38
Total Return	4.57%
Tr YTD	23.74
Tr15y	591.68%
Tr1m	-0.92%
Tr1w	-1.09%
Tr3m	14.27%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	28
Analyst Count Top	16
Analyst Price Target Top	$136
Analyst Ratings	Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$0.23
Earnings EPS Estimate Growth	-89.2
Earnings Revenue Estimate	16,388,251,199.2x
Earnings Revenue Estimate Growth	3.68x
Operating Income	$9.9B
Operating Income Growth	-58.85
Operating Income Growth3 Y	-20.86
Operating Income Growth5 Y	-4.33
Operating margin	14.8
Price target	$137
Price Target Change	$6.45
Price Target Change Top	$5.63

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	2,465,702,855%
Float Percent	99.83%
Net Borrowing	13,798,000,000
Shares Insiders	0.05%
Shares Institutions	81.22%
Shares Out	2,469,824,415
Shares Qo Q	-0.08%
Shares Yo Y	-1.92%
Short Float	1.19%
Short Ratio	2.59
Short Shares	1.19

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$13.3B
Adjusted OCF	17,080,000,000
Average Volume	8,348,768.5x
Bv Per Share	18.58
CAPEX	$-3.8B
Ch10y	101
Ch15y	304.8
Ch1m	-0.92
Ch1w	-1.09
Ch1y	58.89
Ch20y	210.4
Ch3m	13.45
Ch3y	22.26
Ch5y	69.82
Ch6m	7.2
Change	0.03%
Change From Open	-1.98
Close	128.3
Days Gap	2.05
Depreciation Amortization	5,324,000,000
Dollar Volume	905,263,442.8
Earnings Date	2026-08-04
Earnings Time	bmo
EBIT	$6.4B
EBITDA	$6.4B
EPS	$1.27
F Score	3
FCF	$14.1B
FCF EV Yield	3.92x
FCF Per Share	$5.71
Financing CF	852,000,000
Fiscal Year End	December
Founded	2,000
Graham Number	23.06532
Graham Upside	-82.02
Income Tax	$2.8B
Investing CF	-22,464,000,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-08-04
Last Report Date	2026-06-30
Last Split Date	1999-02-17
Last Split Type	Forward
Last10k Filing Date	2026-02-24
Lynch Fair Value	$6.36
Lynch Upside	-95.04
Ma150	118.1
Ma150ch	8.67%
Ma20	127.6
Ma20ch	0.6%
Net CF	-3,334,000,000
Next Earnings Date	2026-10-29
Open	131
Optionable	Yes
P FCF Ratio	22.44
P FCF Ratio SBC	23.81
P OCF Ratio	17.71
P OCF Ratio SBC	18.55
Payment Date	2026-10-07
Position In Range	17.38
Post Close	128.4
Postmarket Change Percent	-0.13
Postmarket Price	$128
Pre Close	128.3
Price Date	2026-08-06
Price EBITDA	$49.66
Relative Volume	0.84x
Revenue	66,569,000,000x
SBC By Revenue	1.23x
Share Based Comp	810,000,000
Tax By Revenue	4.17x
Tax Rate	46.72%
Tr20y	553.94%
Tr6m	8.77%
Us State	New Jersey
Views	331
Volume	7,051,986

Frequently asked questions

About this MRK report

What is the latest published MRK stock rating?

Merck & Co. Inc. is shown with hold in the latest published report, analyzed 2026-05-08. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full MRK analysis?

The full latest published report, analyzed 2026-05-08, lives at /stocks/MRK/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair-value range is used for MRK?

The latest published report analyzed 2026-05-08 frames MRK around USD 95 to USD 147. This is a dated valuation range, not a live market price; check the valuation, sensitivity, and bear-case tabs before making a decision.

How often is the MRK page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-05-08). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

Merck & Co. Inc. (MRK)

Coverage state: Latest published research available

Generate a fresh MRK analysis

Our latest published analysis: MRK rated Hold

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · MRK

Valuation

Profitability

Balance sheet

Trading

Position sizing & entry playbook

Next earnings

Sector percentile context

All MRK indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on MRK

Frequently asked questions